How to Verify GLP-1 and Metabolic Peptides by HPLC and MS
A lab-side verification workflow for Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, MOTS-c, AOD9604, NAD+, and adjacent metabolic-research standards.
Published May 28, 2026 · Updated May 30, 2026 · 7 min read · By Lyochem Regulatory Team
GLP-1-family and metabolic-research compounds are difficult to verify from a supplier name alone. Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, MOTS-c, AOD9604, and NAD+ sit in the same buyer conversation, but they do not all create the same analytical problem. HPLC answers purity and impurity-profile questions. MS answers molecular-weight identity questions. Sequence or orthogonal methods answer the cases where mass alone is not enough.
How do labs verify GLP-1 and metabolic peptides by HPLC and MS?
Labs verify GLP-1 and metabolic peptides by pairing RP-HPLC purity with MS identity evidence, then adding LC-MS/MS sequence confirmation, Edman sequencing, amino acid analysis, water, counter-ion, or impurity-profile review when the molecule is long, modified, first-time sourced, or publication-critical. NAD+ should be verified with coenzyme-appropriate identity and purity assays, not treated as a peptide.
Start with molecule class
| Item | Class | Verification priority |
|---|---|---|
| Semaglutide | GLP-1 receptor agonist peptide | HPLC purity, MS identity, water, counter-ion, stability evidence |
| Tirzepatide | GIP / GLP-1 dual-agonist peptide | HPLC purity, MS identity, sequence confidence for first qualification |
| Retatrutide | GIP / GLP-1 / glucagon tri-agonist research peptide | HPLC purity, MS identity, sequence-level evidence where possible |
| Cagrilintide | Amylin-analog research peptide | HPLC/MS plus component-level documentation if paired with Semaglutide |
| MOTS-c | Mitochondrial-derived peptide research standard | HPLC/MS and sequence confirmation if the study is mechanism-sensitive |
| AOD9604 | GH-fragment research peptide | HPLC/MS, salt form, water content, and impurity-profile review |
| NAD+ | Coenzyme, not peptide | Identity assay, purity method, water/storage guidance, molecule-specific COA |
What HPLC can and cannot prove
RP-HPLC is the first purity screen. It shows the main peak, retention time, related impurities, and relative area percent. For metabolic peptides, it is useful for comparing lot-to-lot impurity profiles and spotting shoulders, late hydrophobic impurities, or unexpected retention-time shifts.
HPLC does not prove sequence. A clean main peak can still be the wrong sequence if the molecule has the same or similar retention behavior. HPLC also does not prove mass, water content, salt form, or biological activity. Treat HPLC as one layer in the release packet, not the whole packet.
What MS can and cannot prove
ESI-MS or LC-MS confirms whether the observed molecular weight matches the theoretical molecule. This is essential for Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, MOTS-c, and AOD9604. For long or modified molecules, the report should show how charge states were interpreted and how closely the observed mass matches theory.
Mass alone does not prove residue order. Isobaric residues, sequence permutations, D/L substitutions, and some modified sequences can pass a mass check while still being wrong for a sequence-sensitive assay. For first-lot qualification, LC-MS/MS sequence evidence or another orthogonal method may be proportionate.
When to add sequence-level evidence
Add LC-MS/MS or other sequence-level evidence when:
- The molecule is long, modified, or expensive enough that a wrong lot creates large downstream cost
- The study is receptor-binding, SAR, mechanism, or publication-critical
- A buyer is qualifying a new supplier for the first time
- Lot-to-lot retention time or impurity profile changes unexpectedly
- The peptide is being transferred to a CRO or external QA team
How Lyochem frames the release packet
Lyochem's role is analytical confidence. A metabolic-research standard should ship with a lot-specific COA, HPLC trace, MS identity report, storage condition, retest date, and method notes. Where the study requires more certainty, Lyochem can scope sequence confirmation, impurity-profile explanation, or custom analytical work before the buyer commits to scale.
Talk to our regulatory team
Need HPLC/MS verification for a metabolic peptide lot?
Send the molecule, target purity, intended assay, and whether this is first-lot qualification. Lyochem will map the analytical packet before quote.
Frequently asked questions
- What CAS numbers and molecular weights identify Semaglutide, Tirzepatide, and Retatrutide?
- Semaglutide is CAS 910463-68-2 (C187H291N45O59, average MW 4113.58 g/mol), a 31-amino-acid selective GLP-1 receptor agonist. Tirzepatide is CAS 2023788-19-2 (C225H348N48O68, MW 4813.45 g/mol), a 39-amino-acid GIP / GLP-1 dual agonist. Retatrutide is CAS 2381089-83-2, a 39-amino-acid GIP / GLP-1 / glucagon tri-agonist whose precise formula and salt mass are best read from the lot COA. A verification workflow confirms each by ESI-MS within 0.5 Da of the theoretical mass for the supplied form.
- Is HPLC purity enough to confirm a GLP-1 peptide, or do you also need mass spec?
- HPLC purity alone is not enough. RP-HPLC shows the main-peak area percent and impurity profile, but a clean peak can still be the wrong molecule if it co-elutes with the target. ESI-MS or LC-MS confirms the molecular-weight identity. The two are complementary: HPLC answers 'how pure', MS answers 'is it the right molecule'. For first-lot supplier qualification of a long peptide like Tirzepatide or Retatrutide, add LC-MS/MS sequence verification because mass alone cannot resolve closely-related deletion sequences.
- What documentation should a research lab ask for when sourcing GLP-1 peptides?
- Request a lot-specific COA carrying: RP-HPLC purity (gradient method, UV 214 nm), ESI-MS identity within 0.5 Da of theoretical, sequence confirmation by LC-MS/MS, counter-ion content, peptide content (% net peptide), water content by Karl Fischer, storage condition, and retest date. For in-vivo metabolic-model work, also request bacterial endotoxin (LAL). Ask whether the raw chromatogram and mass-spec files are available as COA attachments so the values can be cited in a methods section.
- How is Cagrilintide verified when it is studied together with Semaglutide (CagriSema)?
- Verify each component against its own analytical packet before combining. Cagrilintide (CAS 1415456-99-3, a long-acting amylin analog) and Semaglutide act through different receptors, so the methodologically clean approach is to confirm identity and purity of each separately by HPLC + MS, then prepare the combination in-protocol. A pre-mixed blend obscures the per-component data a citable methods section needs, which is why separate characterized lots are preferable for research.